Primary Biliary Cholangitis Market Size and Forecasts (2021 - 2031), Global and Regional Share, Trends, and Growth Opportunity Analysis
MARKET INTRODUCTION
Primary biliary cholangitis (PBC) previously known as Primary Biliary Cirrhosis, is a chronic liver disease that originates in the bile ducts. The bile ducts are damaged, as in primary biliary cirrhosis and harmful substances may build up in liver, which leads to irreversible scarring of liver tissue. PBC is considered as autoimmune disease in which body turn against own cells. The primary biliary cholangitis develop slowly.
MARKET DYNAMICS
The primary biliary cholangitis market is expected to grow in coming years owing to factors such as increase in research and development activities for development of medication, increasing number of patients suffering from primary biliary cholangitis and others. On the other hand increase in approvals of drugs to treat PBC by Food and Drug Administration (FDA) is likely to offer opportunities in market.
MARKET SCOPE
The "Global Primary Biliary Cholangitis Market Analysis to 2028" is a specialized and in-depth study with a special focus on the global market trend analysis. The report aims to provide an overview of primary biliary cholangitis market with detailed market segmentation by treatment type, end user and geography. The global primary biliary cholangitis market is expected to witness high growth during the forecast period. The report provides key statistics on the market status of the leading primary biliary cholangitis market players and offers key trends and opportunities in the market.
MARKET SEGMENTATION
The global primary biliary cholangitis market is segmented on the basis of treatment type and end user. Based on treatment type, the market is segmented as drugs and liver transplantation. The drug segment is further classified into symptomatic relief treatment, ursodeoxycholic (UDCA) and obeticholic acid (ocaliva). Based on end user the primary biliary cholangitis market is segmented hospital pharmacies, retail pharmacies and online pharmacies. REGIONAL FRAMEWORK
The report provides a detailed overview of the industry including both qualitative and quantitative information. It provides overview and forecast of the global primary biliary cholangitis market based on various segments. It also provides market size and forecast estimates from year 2020 to 2028 with respect to five major regions, namely; North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South & Central America. The primary biliary cholangitis market by each region is later sub-segmented by respective countries and segments. The report covers analysis and forecast of 18 countries globally along with current trend and opportunities prevailing in the region.
The report analyzes factors affecting primary biliary cholangitis market from both demand and supply side and further evaluates market dynamics effecting the market during the forecast period i.e., drivers, restraints, opportunities and future trend. The report also provides exhaustive PEST analysis for all five regions namely; North America, Europe, APAC, MEA and South & Central America after evaluating political, economic, social and technological factors effecting the primary biliary cholangitis market in these regions.
By Treatment Type
By Distribution Channel
MARKET PLAYERS
The reports cover key developments in the primary biliary cholangitis market as organic and inorganic growth strategies. Various companies are focusing on organic growth strategies such as product launches, product approvals and others such as patents and events. Inorganic growth strategies activities witnessed in the market were acquisitions and partnership & collaborations. These activities have paved way for expansion of business and customer base of market players. The market players from primary biliary cholangitis market are anticipated to lucrative growth opportunities in the future with the rising demand for primary biliary cholangitis in the global market. Below mentioned is the list of few companies engaged in the primary biliary cholangitis market.
The report also includes the profiles of key primary biliary cholangitis market companies along with their SWOT analysis and market strategies. In addition, the report focuses on leading industry players with information such as company profiles, components and services offered, financial information of last 3 years, key development in past five years.
Primary biliary cholangitis (PBC) previously known as Primary Biliary Cirrhosis, is a chronic liver disease that originates in the bile ducts. The bile ducts are damaged, as in primary biliary cirrhosis and harmful substances may build up in liver, which leads to irreversible scarring of liver tissue. PBC is considered as autoimmune disease in which body turn against own cells. The primary biliary cholangitis develop slowly.
MARKET DYNAMICS
The primary biliary cholangitis market is expected to grow in coming years owing to factors such as increase in research and development activities for development of medication, increasing number of patients suffering from primary biliary cholangitis and others. On the other hand increase in approvals of drugs to treat PBC by Food and Drug Administration (FDA) is likely to offer opportunities in market.
MARKET SCOPE
The "Global Primary Biliary Cholangitis Market Analysis to 2028" is a specialized and in-depth study with a special focus on the global market trend analysis. The report aims to provide an overview of primary biliary cholangitis market with detailed market segmentation by treatment type, end user and geography. The global primary biliary cholangitis market is expected to witness high growth during the forecast period. The report provides key statistics on the market status of the leading primary biliary cholangitis market players and offers key trends and opportunities in the market.
MARKET SEGMENTATION
The global primary biliary cholangitis market is segmented on the basis of treatment type and end user. Based on treatment type, the market is segmented as drugs and liver transplantation. The drug segment is further classified into symptomatic relief treatment, ursodeoxycholic (UDCA) and obeticholic acid (ocaliva). Based on end user the primary biliary cholangitis market is segmented hospital pharmacies, retail pharmacies and online pharmacies. REGIONAL FRAMEWORK
The report provides a detailed overview of the industry including both qualitative and quantitative information. It provides overview and forecast of the global primary biliary cholangitis market based on various segments. It also provides market size and forecast estimates from year 2020 to 2028 with respect to five major regions, namely; North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South & Central America. The primary biliary cholangitis market by each region is later sub-segmented by respective countries and segments. The report covers analysis and forecast of 18 countries globally along with current trend and opportunities prevailing in the region.
The report analyzes factors affecting primary biliary cholangitis market from both demand and supply side and further evaluates market dynamics effecting the market during the forecast period i.e., drivers, restraints, opportunities and future trend. The report also provides exhaustive PEST analysis for all five regions namely; North America, Europe, APAC, MEA and South & Central America after evaluating political, economic, social and technological factors effecting the primary biliary cholangitis market in these regions.
Primary Biliary Cholangitis Market Report Analysis
Primary Biliary Cholangitis Market
-
CAGR (2023 - 2031)XX% -
Market Size 2023
US$ XX Million -
Market Size 2031
US$ XX Million
Report Coverage
- Market size and forecast at global, regional, and country levels for all the key market segments covered under the scope
- Key future trends
- Detailed PEST/Porter’s Five Forces and SWOT analysis
- Industry landscape and competition analysis & recent developments
- Detailed company profiles
- Global and regional market analysis covering key market trends, major players, regulations, and recent market developments
Key Players
- Zydus Pharmaceuticals, Inc.
- Tagi Pharma, Inc.
- Intercept Pharmaceuticals, Inc.
- ALLERGAN
- Amneal Pharmaceuticals LLC
- Mylan N.V
- Lannett
- Hikma Pharmaceuticals PLC
- Gemini Pharmaceuticals.
Regional Overview
- North America
- Europe
- Asia-Pacific
- South and Central America
- Middle East and Africa
Market Segmentation
By Treatment Type
- Drugs
- Liver Transplantation
By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.
The reports cover key developments in the primary biliary cholangitis market as organic and inorganic growth strategies. Various companies are focusing on organic growth strategies such as product launches, product approvals and others such as patents and events. Inorganic growth strategies activities witnessed in the market were acquisitions and partnership & collaborations. These activities have paved way for expansion of business and customer base of market players. The market players from primary biliary cholangitis market are anticipated to lucrative growth opportunities in the future with the rising demand for primary biliary cholangitis in the global market. Below mentioned is the list of few companies engaged in the primary biliary cholangitis market.
The report also includes the profiles of key primary biliary cholangitis market companies along with their SWOT analysis and market strategies. In addition, the report focuses on leading industry players with information such as company profiles, components and services offered, financial information of last 3 years, key development in past five years.
- Zydus Pharmaceuticals, Inc.
- Tagi Pharma, Inc.
- Intercept Pharmaceuticals, Inc.
- ALLERGAN
- Amneal Pharmaceuticals LLC
- Mylan N.V
- Lannett
- Hikma Pharmaceuticals PLC
- Gemini Pharmaceuticals.
- Bristol-Myers Squibb Company
Primary Biliary Cholangitis Market Report Scope
| Report Attribute | Details |
|---|---|
| Market size in 2023 | US$ XX Million |
| Market Size by 2031 | US$ XX Million |
| Global CAGR (2023 - 2031) | XX% |
| Historical Data | 2021-2022 |
| Forecast period | 2024-2031 |
| Segments Covered |
By Treatment Type
|
| Regions and Countries Covered | North America
|
| Market leaders and key company profiles |
- Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.
Report Coverage
Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends
Segment Covered
This text is related
to segments covered.
Regional Scope
North America, Europe, Asia Pacific, Middle East & Africa, South & Central America
Country Scope
This text is related
to country scope.
The List of Companies
1. Zydus Pharmaceuticals, Inc.
2. Tagi Pharma, Inc.
3. Intercept Pharmaceuticals, Inc.
4. ALLERGAN
5. Amneal Pharmaceuticals LLC
6. Mylan N.V
7. Lannett
8. Hikma Pharmaceuticals PLC
9. Gemini Pharmaceuticals.
10. Bristol-Myers Squibb Company
1. Zydus Pharmaceuticals, Inc.
2. Tagi Pharma, Inc.
3. Intercept Pharmaceuticals, Inc.
4. ALLERGAN
5. Amneal Pharmaceuticals LLC
6. Mylan N.V
7. Lannett
8. Hikma Pharmaceuticals PLC
9. Gemini Pharmaceuticals.
10. Bristol-Myers Squibb Company
Get Free Sample For